- Home
- ACT vs PTGX Comparison
ACT vs PTGX Comparison
Compare ACT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACT | PTGX |
|---|---|---|
| Founded | 1981 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.4B |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | ACT | PTGX |
|---|---|---|
| Price | $42.07 | $99.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $44.25 | ★ $108.23 |
| AVG Volume (30 Days) | 268.9K | ★ 429.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | ★ 3.43 | N/A |
| EPS | ★ 1.18 | 0.05 |
| Revenue | ★ $1,235,827,000.00 | N/A |
| Revenue This Year | $4.06 | $874.25 |
| Revenue Next Year | $2.33 | N/A |
| P/E Ratio | ★ $35.65 | $1,996.00 |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $33.94 | $47.53 |
| 52 Week High | $44.80 | $107.84 |
Technical Indicators
Market Signals| Indicator | ACT | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 47.90 |
| Support Level | $41.98 | $96.36 |
| Resistance Level | $44.47 | $100.00 |
| Average True Range (ATR) | 0.90 | 4.06 |
| MACD | -0.17 | -0.18 |
| Stochastic Oscillator | 12.55 | 33.37 |
Price Performance
Historical ComparisonAbout ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The company operates in a single reportable segment namely Mortgage Insurance The principal mortgage insurance customers are originators of residential mortgage loans that determines the mortgage insurer or insurers to be used for the placement of mortgage insurance written on loans originated. The company is engaged in writing and assuming residential mortgage guaranty insurance.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.